首页> Journal of Clinical Oncology> Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

导出原文传递

翻译打印收藏纠错

第一作者： Valcamonico,F.

作者： Valcamonico,F. ^[1] ; Petrelli,F. ^[2] ; Ferrari,L. ; Ferrari,V. ; Grisanti,S. ; Barni,S. ; Berruti,A.

作者单位： University of Brescia, Azienda Ospedaliera Spedali CiviliBrescia, Italy ^[1] Azienda Ospedaliera TreviglioTreviglio, Italy ^[2]

发布时间 2015-02-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览5

Journal of Clinical Oncology

2014年32卷32期

3684-3685页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览5

Journal of Clinical Oncology

2014年32卷32期

3684-3685页

检索历史清除

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

Journal of Clinical Oncology

相似文献

同项目论文

Journal of Clinical Oncology

相关期刊

检索历史清除